Lincoln Pharmaceuticals Ltd · NSE:LINCOLN
Lincoln Pharmaceuticals — Q4 FY2025 Earnings Presentation
24 slides from Lincoln Pharmaceuticals's earnings presentation, 2025
Slide 1: Q4 FY2025 Earnings Presentation
Q4 FY2025 PHARMACEUTICALS LTD Earnings Presentation HEALTHCARE FOR ALL GROWING IS COMMITEMENT. www.lincolnpharma.com
Slide 2: Disclaimer
Disclaimer The information, statements and analysis made in this presentation describing Company’s objectives, projections and estimates are forward looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which cou
Slide 3: Corporate Overview
Corporate Overview Background Product Portfolio Manufacturing Exports Established in the year 1979, 1700 registered products Manufacturing facility at Khatraj, Exports contribute 62.1% in FY25; Lincoln Pharma has developed and another 700 in pipeline. Ahmedabad and Mehsana, Gujarat. Domestic Sales c
Slide 4: FY25 Business Performance & Future Road Map
FY25 Business Performance & Future Road Map • Company has continued its growth journey while maintaining a net debt-free status. New product launches in domestic and export markets have strengthened company’s market presence. Company is committed to significantly improve growth going forward. The co
Slide 5: FY25 Consolidated Results
FY25 Consolidated Results TOTAL INCOME EBITDA NET PROFIT 614.97 645.71 134.33 123.97 93.37 82.44 FY24 FY25 FY24 FY25 FY24 FY25 Fig (RsCr) Q4 FY2025 EarningPresentation
Slide 6: Q4 FY25 Performance – Focused Therapeutic Areas
Q4 FY 25 Performance – Focused Therapeutic Areas Therapy Area Q4 FY25 Q4 FY24 General Anti Infectives 26.3% 27.9% Respiratory Systems 8.3% 8.6% 26.50% 26.30% 27.20% 27.90% Alimentary Tract andMetabolism 6.3% 5.2% Genito Urinary System and Sex Hormones 1.3% 1.3% Musculo-Skeletal System 16.7% 16.3% Q4
Slide 7: FY25 Performance Overview
FY25 Performance Overview CONSOLIDATED FINANCIAL PERFORMANCE (Rs in Cr.) PARTICULARS Q4 Y-o-Y 12 Months Y-o-Y FY2025 FY2024 Growth (%) FY2025 FY2024 Growth (%) Total Income 161.30 149.51 7.89% 645.71 614.97 5.0% EBITDA 19.84 25.40 -21.89% 123.97 134.33 -7.71% Profit BeforeTax 16.25 22.22 -26.87% 109
Slide 8: About Lincoln Pharmaceuticals Ltd
About Lincoln Pharmaceuticals Ltd Providing Affordable And Innovative Medicines For Healthier Lives. Vision To spark a universal attempt to uncover cures of diseases by focused and targeted R&D, through forging strategic alliances both domestically and internationally. Mission Focused on delivering
Slide 9: Key Milestones
Key Milestones 1979 1996-97 2010-11 2016-17 Listed on NSE. Domestic marketexpansion; Install 2.1 MW windmill Launched nextgeneration Received WHO-GMPfor Covered 80% of India market. in addition to 6000 progesterone therapy - plant/production unit. KVA in 2009. ProlinSpray. Lincoln wasincorporated an
Slide 10: Growth Drivers – Ready for the Next Big Leap
Growth Drivers – Ready for the Next Big Leap CAPEX The company has completed the expansion of its Cephalosporin plant in Mehsana, Gujarat, and has commenced commercial production, with sales initiated in domestic markets. Plans are underway to register the product for export to multiple countries. C
Slide 11: Five Years Financial Overview
Lincoln Pharmaceuticals Ltd – Five Years Financial Overview Year Total Income EBITDA Net Profit EPS Share Price FY 25 645.71 123.97 82.44 41.11 551.55 FY 20 396.3 76.50 51.50 25.72 133.80 5 Yrs CAGR 10.26% 10.14% 9.87% 9.87% 32.75% Book Yalue (Per Share) Market Cap (Rs Cr) Net Debt (Rs Cr) 335 1173
Slide 12: Business Revenue Mix
Business Revenue Mix FY13 FY19 FY25 45.0 37.9% 25.5% 74.5% 55.0% 62.1% DOMESTIC SALES EXPORT Q4 FY2025 EarningPresentation
Slide 13: Global Footprints
Global Footprints Presence over 60+ countries in Europe, Canada, Latin & North America, Africa, Asia Pacific, South East Asia, and 26 states across India. Srinagar Jammu Chandigarh Uttrakhand North America: Ambala Europe: Delhi Ghaziabad Canada. France. Lucknow Guwahati Jaipur Patna Ranchi Ahmedabad
Slide 14: Research & Development
Research & Development NDDS Formulations Introduced First Time In India by Lincoln Anti-Fungal VaginaSpray. Diclofenac RectalSpray. Sildenafil Oral Spray. Ondansetron Hydrochloride Oral Spray (DOMI-UP). Paracetamol 1000mg Programmed ReleaseTablet (PA-12). Micronized Progesterone Vaginal Spray (PROLI
Slide 15: Innovations – LINCOLN PHARMA
Innovations – LINCOLN PHARMA Q4 FY2025 EarningPresentation
Slide 16: New Launches – Domestic Market
New Launches – Domestic Market Q4 FY2025 EarningPresentation
Slide 17: New Launches – International Markets
New Launches – International Markets Q4 FY2025 EarningPresentation
Slide 18: Wide Spectrum of Therapeutic Coverage
Wide Spectrum of Therapeutic Coverage Cough &Cold/ Dermatologist Gyneacological Sterile Ophthalmic Gastro Intestinal Anti Allergic/ Preparation Products Eye Drops/ Range Anti-asthmatics Ointment Vitamins/ Anti-bacterial/ Anti-viral/ Analgesic/ Anti-Malarial M inerals/ Otology Anti-fungal Anti-pyreti
Slide 19: Best In Class Facilities – Khatraj, Gujarat
Best In Class Facilities – Khatraj, Gujarat Certification EU-GMP, TGA, WHO-GMP Certified; ISO 9001:2015; ISO-14001:2015 and ISO-45001:2018 Certified. R&D Center Approved by Government of India; Team of 30 plus scientists for R&D. Green Energy Dosage Forms Produced at Unit 1 Dosage Forms Produced at
Slide 20: Best in Class Facilities – Mehsana, Gujarat
Best in Class Facilities – Mehsana, Gujarat WHO-GMP Certified; BOMRA Certified; ISO 9001:2015; ISO-14001:2015 and Certification ISO-45001:2018 Certified. Approved Team of 10 plus scientists for R&D. R&D Center Dosage Forms Produced at Unit 3 OSD and Dry Powder Injection Description Size Annual Capac
Slide 21: Financial Highlights
Financial Highlights TOTALINCOME NET PROFIT 615.0 645.7 93.4 82.4 532.8 72.9 482.1 69.4 428.7 62.3 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 EBITDA NET WORTH Fig (RsCr) 134.3 671.7 124.0 592.8 105.5 111.7 92.8 502.5 432.9 366.4 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 Q4 FY2025 Earn
Slide 22: Profitability Ratios
Profitability Ratios EBITDA MARGIN PAT MARGIN 21.6% 21.9% 21.8% 14.5% 14.4% 15.2% 21.0% 13.7% 19.2% 12.8% FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 ROCE RONW 22.6% 21.9% 20.4% 17.0% 19.9% 16.0% 15.7% 14.5% 16.1% 12.3% FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 Q4 FY2025 EarningPresent
Slide 23: Share Holding Information
Share Holding Information Particulars March 2025 March 2024 Investor Category No of Shareholders No of Shares Held Holding (%) No of Shareholders No of Shares Held Holding (%) Promoter Group 25 99,69,930 49.78% 25 99,21,430 49.53% Public Holding 31,842 1,00,59,798 50.22% 31,350 1,01,08,298 50.47% To
Slide 24: Location
Location Corporate Office Lincoln House B/h Satyam Complex, Science City Road, Sola Ahmedabad - 380060,Gujarat, India. Phone: +91 - 79 - 4107 8000 l Fax: +91- 79 - 4107 8062 Email: info@lincolnpharma.com Web: www.lincolnpharma.com CIN: L24230GJ1995PLC024288 Darshit Shah Gopal Modi CFO, Lincoln Pharm
Lincoln Pharmaceuticals — Q4 FY2025 Earnings Presentation on 6ix